Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]

  • In development
  • GID-TA11664
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Mavacamten within its marketing authorisation for treating non-obstructive hypertrophic cardiomyopathy (nHCM)